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A workshop, "Molecular and Cellular
Approaches to Extrapolation for Risk
Assessment," was held in Baltimore,
Maryland, USA, 5-6 May 1993. The
workshop was hosted by the Johns
Hopkins Center for Alternatives to Animal
Testing and was sponsored by the
American Forest and Paper Association,
Washington, DC. Forty representatives of
government, industry, and academia met to
discuss the opportunity to use in vitro data
to improve evaluations of human risk, cit-
ing information gaps between animal and
human data sets, and the relatively limited
useofin vitrodata in riskassessments.
The scientific methods of toxicology
are most often used to identify potential
hazards or to evaluate the safety ofspecific
substances under certain experimental con-
ditions. Although current scientific risk
assessments are quantitative in nature, they
are based upon assumptions inherent in
methods of safety evaluation and hazard
identification.
To date, the predominant method is to
test animals and then to extrapolate the
results to humans. Interspecies extrapola-
tions indude route of exposure, dose, and
response. Due to the lack of information
about relevant human responses to chemi-
cal exposures, such extrapolations lead to
uncertainties; these uncertainties result in
decreased confidence in risk estimates.
Even in tier test systems that are signifi-
cantly based on alternative tests, confirma-
tion is obtained through selective testing in
animal species. In vitro data are often
viewed as an additional level of extrapola-
tion. In such schemes, in vitro data may be
used to bolster knowledge about specific
issues ofextrapolation, but the data them-
selves represent an additional source of
uncertainty (Fig. 1A) (1-6).
In this workshop we considered an
alternate scheme, based on the parallelo-
gram approach to extrapolation to man,
that was proposed in the late 1970s by
Sobels (7-9). Although this approach was
originally described for its application to
chemical mutagenesis, its underlying prin-
cipal, "to obtain information on damage
that is hard to measure directly" (8), is rele-
vant to most, ifnotall, biological endpoints
oftoxicity. In Figure 1B, the parallelogram
has been modified to emphasize two
important issues that were considered in
this workshop: interspecies and in vitro-in
vivo extrapolation. This parallelogram pro-
vides a framework for the discussion of
molecular and cellular approaches to
extrapolation for risk assessment and pro-
vides a process for systematic, comparative
biology. In vitro data are used to support
investigations ofmechanism ofaction and,
more specifically, to evaluate the assump-
tion of conserved mechanism of action
among different species. By superimposing
the parallelogram onto the components of
toxicity identified in Figure 2, a rationale is
established for systematic stepwise compar-
isons of specific mechanism of action.
Through such comparisons, it should be
possible to establish whether specific mech-
anistic steps are conserved among species.
Furthermore, once conservation of mecha-
nism is established, subsequent studies can
be used to determine and to compare quan-
titative aspects of dose-response relation-
ships between species. Thus, as previously
noted by Sobels, the parallelogram
approach can be used to provide both qual-
itative and quantitative information that is
directly relevant to estimates ofhuman risk.
Workshop sessions were organized to
emphasize each corner ofthe parallelogram
or to highlight related issues. Before the
meeting, each speaker provided a statement
ofhis or her beliefs concerning the three
most relevant issues and opportunities asso-
ciatedwith molecular andcellularapproach-
es to extrapolation for risk assessment.
Compilation of these statements identified
issues related to four major topics: 1) pre-
dictions, 2) humans, 3) mechanisms, and 4)
regulatory agencies and riskassessment.
Predictions
In vivo responses are often the result of
complex pathological processes, i.e., the
long-term result of multiple factor, multi-
cellular interactions. Even when using sen-
sitive molecular and cellular approaches,
can in vitro data be used to predict likely
outcomes of such processes? For example,
can early markers predict chronic toxicity?
A related issue of prediction concerns the
equivalency ofsensitive biological respons-
es. If different concentration-response
curves are determined for different mark-
ers, which one(s) predicts in vivotoxicity?
These issues related to in vitro-in vivo
extrapolations are significant. When
viewed within the context of a complex
process, e.g., carcinogenesis, it is difficult
to conceptualize an approach for address-
ing these difficulties. However, ifcomplex
biological processes are broken down into
a biologically based dose-response para-
digm, then the specific in vitro-in vivo
comparisons become more focused. As
shown in Figure 2, complex processes can
be subdivided into discrete components
that provide a context for investigations of
specific mechanistic steps. While each
individual component is truly a connected
series of mechanistic steps, the broader
picture depicted in Figure 2 emphasizes
that, for the current status of risk assess-
ments, it may be more useful to obtain
increased knowledge of the entire process,
albeit at a less comprehensive level, than it
is to have complete knowledge about one
or more steps in the process, with little
knowledge ofothers. In general, the over-
all assessment will only be as good as the
least understood component in the mecha-
nism ofthe endpoint ofinterest.
Several speakers raised an interesting
question concerning prediction: are the
responses observed in rodents valid predic-
tors of human toxicity? As discussed
above, the parallelogram provides a frame-
work in which to test the hypothesis of
conserved mechanism ofaction among dif-
ferent species.
Molecular and cellular approaches,
combined with comparative in vitro sys-
tems, provide a method to explore early
biological responses to chemical or physi-
cal agents and the role ofthese early effects
in altered cellular structure and function.
Such studies may lead to an improved
understanding ofmechanism ofaction and
biological determinants ofspecificity. Also,
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Figure 2. The principle of dose-response in risk and safety assessments. In the exposure-dose-response
paradigm [adapted from the National Research Council Committee on Biological Markers (20)], complex
biological processes are divided into discrete components that provide a context for investigations of
specific mechanistic steps. (A) Components of in vivo toxicity. (B) Components of in vitro toxicity. Note
that most ofthe components of in vivotoxicity can be studied in vitro.
Figure 1. The role of in vitro data in extrapola-
tions for risk assessment. (A) The traditional
approach. In vitro data provides specific knowl-
edge about important issues of extrapolation:
route, species and dose. (B) The parallelogram
approach. Modified from Sobels (8) to emphasize
the issues of interspecies and in vitro-in vivo
extrapolation. In this four-cornered experimental
approach to knowledge of mechanism, in vitro
data is used to testthe hypothesis that a specific
mechanism of action is conserved among rodent
and human species. Note that the alternate
hypothesis will still provide information aboutthe
action ofthe test compound in humans.
studies ofthe relationship between concen-
tration and biologically effective dose may
provide insights into the shape of the
dose-response curve in humans, including
even lower levels of exposure. The poten-
tial for this latter opportunity (high to low
dose) comes from the sensitivity ofbiologi-
cal endpoints that are based on specific
molecular and cellular targets.
In terms of linking exposure to
dose-response relationships, several signifi-
cant advancements have been made in the
area of physiologically based pharmacoki-
netic (PBPK) and pharmacodynamic mod-
eling. The concept of surrogate dose, or
dose at the site of molecular action, pro-
vides a bridge between in vivo exposure
and specific biological responses measured
either in vivo or in vitro. As such, these
modeling techniques may provide a con-
tinuum in investigations of mechanism, as
experimental systems move between ani-
mals and cells in culture (10).
Human Cells
At present, the mechanism of action of
many chemicals in humans is not fully
understood. This includes knowledge of
distribution, metabolism, specific cellular
targets, sensitivity of specific cell popula-
tions, and repair capacity. This general lack
of information concerning toxicity in
humans is further complicated by the expo-
sure ofpeople to multiple chemicals over a
lifetime that is considerably longer than
that ofrodents. A second issue relates to the
limited availability ofhuman specimens.
Human specimens, including tissues,
slices, organ cultures, cocultures, or prima-
ry cells in culture, provide tremendous
opportunity to investigate human biologi-
cal response(s) to a variety ofchemical and
physical agents (11). When combined with
modern methods ofmolecular biology and
biochemistry to provide human recombi-
nant DNA probes and expressed and puri-
fied human proteins, such studies can be
used to identify primary biological end-
points relevant to human exposures (12)
and to determine ifthe same critical cellu-
lar target (13) and mechanism (14) respon-
sible for toxicity in animals exist in people.
Corollary to this approach is the under-
standing that the methods developed using
human in vitro systems can be easily
imported as biomarkers into human epi-
demiology studies. Thus human in vitro
studies support both human corners ofthe
parallelogram and provide an opportunity
for improved understanding of human in
vivo responses (15,16). Without such
improved sensitivity of the methods of
human epidemiology or the incorporation
ofhuman in vitro data into the risk charac-
terization process, biologically based risk
assessments will simply represent improved
models for the interpretation ofdata gener-
ated byanimal experimentation.
Mechanisms
Should all tests be relevant mechanistically?
Is correlation sufficient, especially as it
relates to screens, or is it necessary to
demonstrate a mechanistic link to biologi-
cal response? Considerable discussion cen-
tered on the importance of knowledge of
mechanism in decision-making processes.
Both lectures on strategies for implementa-
tion made it clear that correlation is suffi-
cient as a criteria for the application of
screens (rapid tests to determine general or
specific toxicity). In these cases knowledge
ofthe mechanism resulting in the endpoint
oftoxicity is not required. For screens, cur-
rent and future uses of in vitro data offer
great potential to reduce, or eventually
eliminate, the use of animals (17,18). The
importance of these advancements should
not be understated. However, it should be
noted that while correlative studies may
provide useful in-house information for
decision-making, they advance neither the
specific understanding of the endpoint of
toxicity nor the methods to detect and
quantitate such toxicity. For example, the
Draize test, an in vivo screen for ocular and
dermal irritancy, was widely used as a cor-
relative screen for human-use product safe-
ty assessments. If more emphasis had been
placed on obtaining a mechanistic under-
standing ofthis test, its replacement by cell
or organ culture methods would have been
greatly facilitated. Correlative studies do
not provide a foundation for scientific
advancement and, as such, should be used
judiciously to immediately reduce the use
of animals, while mechanistically based
screen replacements with inherent potential
forcontinued improvement are developed.
Mechanism-based approaches to risk
assessment tend toward identification oftrue
risk. Risk assessments that are based on such
information will be based on the best avail-
able science. In turn, this should motivate
good research and promote a self-advancing
field that provides an improved understand-
ing ofhuman risk. Computer-based chemi-
cal databases facilitate the collection, storage,
and retrieval oflarge amounts of informa-
tion. Inherent in these chemical structures
are features that determine biological activity
(19). Studies of structure activity relation-
ships provide the opportunity to advance
from chemical specific risk assessments to
chemical dass-based risk assessments. Both
the concepts ofstructure activity and surro-
gate dose imply the presence ofa critical cel-
lular target. Mechanism-based approaches
implore the identification ofsuch targets and




Several issues were identified that relate to
certainty and uncertainty in risk estimates.
Currently, both the regulatory and legal
systems attempt to classify everything as
safe or hazardous. Is it possible to move
away from this toward a weight-of-evi-
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dence approach? Is the most sensitive
response observed in animals necessarily
the most relevant for human risk assess-
ment? To what extent must we define a
toxic mechanism in vivo as a prerequisite
to gaining regulatory acceptance?
Current use of in vitro data in the risk
assessment process is limited. Advancements
in our abilities to grow and maintain
human specimens, coupled with improve-
ments in the ability to detect and quantitate
specific human molecular targets, suggest
that an important opportunity exists to
improve the understanding of the human
component ofinformation available for risk
assessment. To understand how to incorpo-
rate in vitro data into the risk assessment
process will be difficult, but achievable.
For most ofthe topics discussed during
this workshop we are currently knowledge-
limited, that is, we lack sufficient informa-
tion to move to a totally in vitro based
approach. This information gap encom-
passes fundamental understanding of both
knowledge ofmechanism ofaction and the
availability ofreliable data sets ofsufficient
size to facilitate the recognition ofunderly-
ing general principles. Because of these
limitations, the prerequisite for a prelimi-
nary understanding of mechanism is, in
general, currently obtainable only through
in vivo studies. Such information includes
knowledge of 1) distribution, including
route of administration, dose, and dura-
tion, 2) metabolism and identification of
the proximate toxicant, 3) target tissue and
target cell, including critical cellular con-
centration and relative cell and tissue sensi-
tivities, 4) injury progression and cell-cell
interactions, 5) the capacity for repair,
compensatory responses, and adaptation,
and 6) the potential for chemical interac-
tions, including exposures to mixtures, and
interactions with endogenous chemicals. In
general, for the complex biological
responses depicted in Figure 2, we have lit-
tle understanding of the events that link
altered structure and function to disease.
The availability ofhuman specimens is
limited. The quality ofsuch samples varies,
and this further complicates the issues of
intersample and interindividual variability.
In addition, little information is available
about the influence of cell culture condi-
tions and specific medium constituents on
measurements of biological responses
determined in vitro.
In general, mechanism-based approach-
es are expensive and time consuming to
develop. In addition to being technically
demanding, the results tend to be chemical
specific and indicative of selective toxicity,
as opposed to more general or universal
mechanisms.
Current and Future Uses of
In Vitro Data
Several current uses of in vitro data exist:
1) to select the most appropriate animal
model ofhumans; 2) to provide mechanis-
tic information about in vivo responses; 3)
to screen series of toxicants rapidly; 4) to
screen for ocular, dermal, neurological, and
developmental toxicity; 5) to establish
potential mutagenicity and carcinogenicity;
and 6) to further document the hazardous
nature ofacarcinogen.
Future uses of in vitro data include: 1)
expanded use as screens; 2) reduction or
elimination ofthe use ofanimals for assess-
ments of dermal irritation; 3) determina-
tion ofspecific parameters for PBPK mod-
els; and 4) expanded use in investigations
ofmechanism ofaction, specifically as such
information relates to risk assessment.
Conclusions
This workshop explored many aspects of
the complex issues related to interspecies
extrapolation. The parallelogram approach
provides a rationale for systematic step-wise
comparisons, including in vitro-in vivo
comparisons of rodent and human biology
that provide knowledge of response and
sensitivity to chemical action. Applications
ofmodeling provide important methods to
link in vivo exposures to other endpoints of
in vivo and in vitro biological response. In
reviewing the available methods and experi-
mental systems, a major informational gap
was identified concerning the events that
mechanistically link altered structure and
function to toxicity or disease. Future stud-
ies need to focus on this important area of
limited knowledge, as it appears to be rate
limiting in the overall process to determine
accurate risk estimates.
Given the understanding that chemi-
cal-specific risk assessments are both time
consuming and expensive, considerable
concern remains about the issue of selec-
tive versus universal mechanisms of toxici-
ty. For now, no simple solution is evident.
Minimally, advancements in structure
activity relationships should permit us to
move from chemical-specific risk assess-
ments to those based on chemical class.
Moreover, from the history of mutagene-
sis, it is clear that complete knowledge of
specific mechanisms is not required for
effective determinations of risk estimates.
As in the case of chemical mutagenesis,
unifying concepts of g'eneral mechanisms
may make it possible to develop systems to
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detect and quantify specific chemical
activity. It remains possible that such uni-
fying concepts are inherent in other com-
plex biological process such as dermal irri-
tancy or even cancer, and that such con-
cepts will supersede the need for complete
and specific knowledge of mechanism of
action and permit the development of
effective, general screens based on com-
mon mechanism.
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